



## **Takeda and Enterome Enter Strategic Drug Discovery Collaboration Focused on Microbiome Targets Across Multiple Gastrointestinal Disorders**

**Osaka, Japan, Paris, France and Boston, MA, USA, January 6, 2016** .....

Takeda Pharmaceutical Company Ltd. ([TSE: 4502](#)) and Enterome Bioscience SA ("Enterome") today announced they have entered into a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome).

*"This strategic collaboration with Takeda is a significant achievement for Enterome and represents an important step towards realizing the full potential of our expertise and unique capabilities in unlocking the microbiome to generate new therapeutic solutions to serious diseases,"* commented Pierre Belichard, CEO of Enterome. *"We are delighted to begin this new collaboration, which will combine our continuing leadership in the microbiome space and Takeda's global therapeutic drug discovery and development capabilities. It is also an important step for Enterome towards achieving its ambition to become a leading global biopharmaceutical company in the microbiome space."*

*"At Takeda, innovation is at the core of our efforts to bring new therapies to patients in the future,"* said Gareth Hicks, Ph.D., head of gastroenterology drug discovery for Takeda. *"In partnering with scientists at Enterome, who perform cutting-edge research into microbiome-derived agents, Takeda is able to explore this exciting science and bring innovative therapies forward."*

Enterome will use its proprietary metagenomic platform to support the discovery of potential novel agents (small molecules or biologics) derived from gut bacteria and directed to the GI targets selected by Enterome and Takeda. Takeda has an option to license selected agents on an exclusive global basis and will be responsible for their regulatory and clinical development as well as their commercialization.

Enterome will receive an upfront payment and 3-year R&D funding, and is eligible to receive additional payments for each molecule discovered through the collaboration in the form of option exercise, development, regulatory and commercial milestone payments. In addition, Enterome is eligible to receive potential tiered royalties on the net sales of any products that are commercialized by Takeda. Further details of the agreement were not disclosed.



## About Enterome

Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as gastrointestinal disorders, cancer and metabolic diseases.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.

The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €17.5 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and two strategic investors (Shire & INRA transfer).

*Additional information about Enterome is available through its website : [www.enterome.com](http://www.enterome.com).*

## About Takeda

Located in Osaka, Japan, Takeda (**TSE: 4502**) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.

*Additional information about Takeda is available through its corporate website : [www.takeda.com](http://www.takeda.com).*

## Takeda's Forward-Looking Statements

This press release contains "forward-looking statements." Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as "anticipate," "expect," "project," "continue," "believe," "plan," "estimate," "pro forma," "intend," "potential," "target," "forecast," "guidance," "outlook," "seek," "assume," "will," "may," "should," and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict.



Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development.

The forward-looking statements contained in this press release speak only as of the date of this press release, and neither Enterome nor Takeda undertake any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.

---

## CONTACTS

### For Enterome

Pierre Belichard, CEO  
+33 1 75 77 27 87

David Dible / Mark Swallow / Marine Perrier, Citigate Dewe Rogerson  
+44 207 638 9571  
[enterome@citigatedr.co.uk](mailto:enterome@citigatedr.co.uk)

### For Takeda:

Japanese Media  
Tsuyoshi Tada  
[tsuyoshi.tada@takeda.com](mailto:tsuyoshi.tada@takeda.com)  
+81-3-3278-2417

### Media Outside of Japan

Julia Ellwanger  
[julia.ellwanger@takeda.com](mailto:julia.ellwanger@takeda.com)  
+1 224-554-7681